Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects

Phase 1

Completed

Conditions: Tauopathies

Interventions: Drug: BMS-986168
Drug: BMS-986168 Placebo

First Posted Date: 2014-11-19

Last Posted Date: 2017-11-06

Lead Sponsor: Biogen

Target Recruit Count: 65

Registration Number: NCT02294851

Locations: 🇺🇸
WCCT Global, LLC, Cypress, California, United States
🇺🇸
Covance Clinical Research Unit Inc., Dallas, Texas, United States

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

Phase 3

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Procedure: Sham procedure
Drug: Nusinersen

First Posted Date: 2014-11-17

Last Posted Date: 2021-02-17

Lead Sponsor: Biogen

Target Recruit Count: 126

Registration Number: NCT02292537

Locations: 🇺🇸
UCLA Clinical and Translational Research Center, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 21 locations

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Phase 3

Active, not recruiting

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: Interferon β-1a
Drug: dimethyl fumarate

First Posted Date: 2014-11-05

Last Posted Date: 2024-07-16

Lead Sponsor: Biogen

Target Recruit Count: 156

Registration Number: NCT02283853

Locations: 🇧🇬
MHATNP 'Sv.Naum', EAD, Sofia, Bulgaria
🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel
🇫🇷
Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France

and more 59 locations

Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery

Completed

Conditions: Healthy

First Posted Date: 2014-11-05

Last Posted Date: 2015-10-05

Lead Sponsor: Biogen

Target Recruit Count: 467

Registration Number: NCT02283918

Locations: 🇺🇸
Research Site, Akron, Ohio, United States
🇮🇹
Research site, Roma, Italy

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: peginterferon beta-1a
Drug: Rebif

First Posted Date: 2014-10-21

Last Posted Date: 2015-02-02

Lead Sponsor: Biogen

Target Recruit Count: 30

Registration Number: NCT02269930

Locations: 🇺🇸
Research Site, Evansville, Indiana, United States

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

Phase 4

Terminated

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: natalizumab

First Posted Date: 2014-09-16

Last Posted Date: 2017-06-05

Lead Sponsor: Biogen

Target Recruit Count: 47

Registration Number: NCT02241785

Locations: 🇺🇸
Research Site, Tacoma, Washington, United States

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

Phase 4

Withdrawn

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: BIIB017 (Peginterferon beta-1a)
Drug: Interferon Beta

First Posted Date: 2014-09-09

Last Posted Date: 2014-11-17

Lead Sponsor: Biogen

Registration Number: NCT02234869

Plegridy Observational Program

Completed

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Drug: peginterferon beta-1a

First Posted Date: 2014-09-03

Last Posted Date: 2022-09-26

Lead Sponsor: Biogen

Target Recruit Count: 1208

Registration Number: NCT02230969

Locations: 🇬🇧
Research Site, Swansea, United Kingdom
🇩🇰
Research site, Glostrup, Denmark

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04958242
Drug: Placebo

First Posted Date: 2014-08-29

Last Posted Date: 2020-01-07

Lead Sponsor: Biogen

Target Recruit Count: 12

Registration Number: NCT02228395

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIB061
Other: Placebo

First Posted Date: 2014-08-29

Last Posted Date: 2016-06-15

Lead Sponsor: Biogen

Target Recruit Count: 56

Registration Number: NCT02228707

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy